Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

ABSTRACT:

Purpose

First-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.

Methods

We conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.

Results

51.39% of patients experienced endocrine irAEs, inc

SUBMITTER: Marrano N 

PROVIDER: S-EPMC12924852 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature